The study of 57 patients with acute graft-versus-host disease (aGVHD) also showed that patients tolerated the treatment, offering promise for preventing and managing the complication of transplantation, which affects up to half of patients.
Initiating ruxolitinib treatment early on can lower the risk and severity of acute graft-versus-host disease (aGVHD) in patients with acute leukemia undergoing alternative donor hematopoietic stem cell transplantation (HSCT), found a new study published in Scientific Reports.
The study of 57 patients with aGVHD also showed they tolerated the treatment, offering promise for preventing and managing the complication of transplantation, which affects up to half of patients.
“Alternative donors remain an important source. Alternative donor–HSCT has achieved good results; the 4-year overall survival (OS) and disease-free survival (DFS) can be more than 80%,” explained the researchers. “However, transplant-related complications are still pivotal factors decreasing the success of transplantation. Especially aGVHD is still a common serious complication of allo-HSCT, seriously affecting the survival and prognosis of patients.”
The group of patients included in the study were split up to receive either ruxolitinib (n = 41) or to receive aGVHD prohphylaxis with cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil (controls; n = 16).
Patients receiving ruxolitinib were approximately half as likely to experience a GVHD (22% vs 50%). They were also significantly less likely to experience grade 3-4 disease (7.3% vs 28.6%).
Between the 2 groups, there were no significant differences in incidence of chronic GVHD; hemorrhagic cystitis; pulmonary, intestinal, Epstein-Barr virus, or cytomegalovirus infection; relapse; death; or nonrelapse mortality.
“Although ruxolitinib had a significant effect on the prevention and treatment of GVHD, some problems still needed to be resolved,” noted the researchers. “First, the perfect time to apply ruxolitinib to prevent GVHD: Are neutrophils implanted, or both neutrophils and platelets implanted? Second, the perfect time to discontinue ruxolitinib: Can we quickly discontinue other immunosuppressants instead of stopping ruxolitinib to reduce the incidence of infection without significant cytopenia after engraftment?”
Fifty-five of the patients achieved reconstitution of hematopoiesis; 2 patients in the control group experienced failure as a result of early graft rejection and serious infection. There were no significant differences in survival, with a 2-year OS rate of 42.9% among controls and a 53.7% 2-year OS rate among those receiving ruxolitinib. Two-year DFS was 32.1% among controls and 46.3% among patients receiving ruxolitinib.
Large multicenter randomized clinical trials should be conducted to validate their findings, the authors concluded.
Reference
Zhang B, Chen L, Zhou J, et al. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. Sci Rep. 2021;11(1):8501. doi:10.1038/s41598-021-88080-3
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More